E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 10/5/2005 in the Prospect News Biotech Daily.

ZymoGenetics' orphan status a plus, Merrill says

ZymoGenetics Inc.'s announcement Wednesday that the U.S. Food and Drug Administration designated the company's melonoma treatment Interleukin-21 as an orphan drug is viewed by Merrill Lynch analyst Hari Sambasivam as favorable for the company. Merrill Lynch said the orphan drug designation provides seven years of exclusivity for the product, a positive move for the Seattle-based biopharmaceutical company. Shares were down $0.70, or 3.92%, at $17.16 on volume of 265,581 shares versus the three-month running average of 276,063 shares.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.